XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)
$ in Thousands
Common stock
Additional paid-in capital
Cumulative Effect Adjustment
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Cumulative Effect Adjustment
Accumulated deficit
Cumulative Effect Adjustment
Total
Balance (in shares) at Dec. 31, 2020 69,718,096              
Balance at the beginning of the period at Dec. 31, 2020 $ 70 $ (175,236) $ 2,171,746 $ (60,957) $ 54,796 $ (1,628,877) $ (120,440) $ 481,982
Increase (Decrease) in Stockholders' Equity                
Exercise of options (in shares) 475,942              
Exercise of options     13,144         13,144
Restricted stock vesting and issuance (in shares) 292,171              
Issuance of common stock in connection with an employee stock purchase plan (in shares) 73,121              
Issuance of common stock in connection with an employee stock purchase plan     2,627         2,627
Share-based compensation expense     51,406         51,406
Net loss           (247,012)   (247,012)
Comprehensive income (loss)       14,870       14,870
Balance (in shares) at Jun. 30, 2021 70,559,330              
Balance at the end of the period at Jun. 30, 2021 $ 70   2,063,687 (46,087)   (1,821,093)   196,577
Balance (in shares) at Mar. 31, 2021 70,405,905              
Balance at the beginning of the period at Mar. 31, 2021 $ 70   2,033,972 (38,743)   (1,702,723)   292,576
Increase (Decrease) in Stockholders' Equity                
Exercise of options (in shares) 60,159              
Exercise of options     1,389         1,389
Restricted stock vesting and issuance (in shares) 20,145              
Issuance of common stock in connection with an employee stock purchase plan (in shares) 73,121              
Issuance of common stock in connection with an employee stock purchase plan     2,627         2,627
Share-based compensation expense     25,699         25,699
Net loss           (118,370)   (118,370)
Comprehensive income (loss)       (7,344)       (7,344)
Balance (in shares) at Jun. 30, 2021 70,559,330              
Balance at the end of the period at Jun. 30, 2021 $ 70   2,063,687 (46,087)   (1,821,093)   196,577
Balance (in shares) at Dec. 31, 2021 70,828,226              
Balance at the beginning of the period at Dec. 31, 2021 $ 71   2,123,606 (24,282)   (2,097,957)   1,438
Increase (Decrease) in Stockholders' Equity                
Exercise of options (in shares) 125,020              
Exercise of options     3,198         3,198
Restricted stock vesting and issuance (in shares) 461,380              
Issuance of common stock in connection with an employee stock purchase plan (in shares) 91,263              
Issuance of common stock in connection with an employee stock purchase plan     3,107         3,107
Share-based compensation expense     54,319         54,319
Net loss           (278,813)   (278,813)
Comprehensive income (loss)       34,533       34,533
Balance (in shares) at Jun. 30, 2022 71,505,889              
Balance at the end of the period at Jun. 30, 2022 $ 71   2,184,230 10,251   (2,376,770)   (182,218)
Balance (in shares) at Mar. 31, 2022 71,337,041              
Balance at the beginning of the period at Mar. 31, 2022 $ 71   2,152,639 (18,608)   (2,224,683)   (90,581)
Increase (Decrease) in Stockholders' Equity                
Exercise of options (in shares) 27,832              
Exercise of options     754         754
Restricted stock vesting and issuance (in shares) 49,753              
Issuance of common stock in connection with an employee stock purchase plan (in shares) 91,263              
Issuance of common stock in connection with an employee stock purchase plan     3,107         3,107
Share-based compensation expense     27,730         27,730
Net loss           (152,087)   (152,087)
Comprehensive income (loss)       28,859       28,859
Balance (in shares) at Jun. 30, 2022 71,505,889              
Balance at the end of the period at Jun. 30, 2022 $ 71   $ 2,184,230 $ 10,251   $ (2,376,770)   $ (182,218)